ROVI — Laboratorios Farmaceuticos Rovi SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Market Cap
€4.40bn
Enterprise Value
€4.45bn
Revenue
€829.51m

Annual income statement for Laboratorios Farmaceuticos Rovi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	381	420	649	818	830
Cost of Revenue
Gross Profit	215	241	385	520	492
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	338	345	467	562	609
Operating Profit	42.8	74.7	181	256	220
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	41.9	72.6	183	258	220
Provision for Income Taxes
Net Income After Taxes	39.3	61.1	153	200	170
Minority Interest
Net Income Before Extraordinary Items
Net Income	39.3	61.1	153	200	170
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	39.3	61.1	153	200	170
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.718	1.16	2.79	3.73	3.2
Dividends per Share